ICON Forms Strategic Alliance With Boston Clinical Research Institute
ICON announced a strategic alliance with Boston Clinical Research Institute (BCRI), an Academic Research Organisation based in Boston, Massachusetts. The alliance will combine BCRI’s respected leadership in clinical strategy, study planning, and academic relationships with ICON’s experience in the execution of global clinical trials.
BCRI provides scientific consultancy in study design using practicing clinicians and key opinion leaders from medical institutions, and also maintains a network of global investigators in all of the medical specialties and subspecialties. BCRI also provides academic leadership for Steering Committees, Advisory Panel Participation, Endpoint Committees, Core Laboratory Services, and Data Safety and Monitoring Boards.
“We are extremely pleased to announce the partnership with ICON,” commented Dr. Michael Gibson, Founder and Senior Consultant at BCRI. “We believe that the future of clinical research is collaboration between the ARO and the CRO. ICON clearly recognizes the incremental benefits of collaboration with the thought leaders in the medical community to optimize study planning, execution, and credibility.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
